Advertisement
Canada markets close in 5 hours 38 minutes

  • S&P/TSX

    21,716.68
    -157.04 (-0.72%)
     

  • S&P 500

    5,009.90
    -61.73 (-1.22%)
     

  • DOW

    37,827.45
    -633.47 (-1.65%)
     

  • CAD/USD

    0.7295
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    82.46
    -0.35 (-0.42%)
     

  • Bitcoin CAD

    87,317.07
    -3,150.66 (-3.48%)
     

  • CMC Crypto 200

    1,373.59
    -8.99 (-0.65%)
     

  • GOLD FUTURES

    2,333.90
    -4.50 (-0.19%)
     

  • RUSSELL 2000

    1,960.12
    -35.31 (-1.77%)
     

  • 10-Yr Bond

    4.7270
    +0.0750 (+1.61%)
     

  • NASDAQ

    15,490.59
    -222.16 (-1.41%)
     

  • VOLATILITY

    17.39
    +1.42 (+8.89%)
     

  • FTSE

    8,049.92
    +9.54 (+0.12%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6806
    -0.0013 (-0.19%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Why ChemoCentryx Stock Tanked in 2021

George Budwell, The Motley Fool
·2 min read
Why ChemoCentryx Stock Tanked in 2021

Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.

Continue reading